Description

Repligen’s $1.5 Billion Acquisition Could Reshape Its Growth Story!

Repligen Corporation has agreed to acquire BioLife Solutions (NASDAQ:BLFS) for approximately $1.5 billion, combining cash and stock in a transaction designed to strengthen Repligen’s position in cell therapy manufacturing. BioLife shareholders would receive $11.25 in cash and 0.1442 Repligen shares for each BioLife share, implying consideration of $31 per share. The proposed acquisition follows a strong operating period for Repligen, which reported 11% organic revenue growth in the first quarter of 2026 and preliminary second-quarter organic growth of approximately 13%. Management expects the transaction to close in the fourth quarter, subject to regulatory approval and a BioLife shareholder vote. Strategically, the deal would add a high-growth, high-margin consumables platform centered on CryoStor preservation media while expanding Repligen’s exposure to commercial and clinical cell therapies. Financially, management expects revenue growth, margin, and adjusted earnings accretion, supported by cost savings, manufacturing improvements, and cross-selling opportunities across both companies’ customer bases globally.